TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00528931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: collagenase clostridium histolyticum
Description: Single dose of AA4500 0.58 mg into the cord
Study: NCT00937677

Intervention type: DRUG
Intervention: Tysabri
Description: Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.~Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.~TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial.
Study: NCT01669577

Intervention type: PROCEDURE
Intervention: analysis of blood samples and clinical features
Description: clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
Study: NCT04222816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: Lithium carbonate 800-900 mg orally daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: Lithium carbonate 800-900 mg orally daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium chloride
Description: Sodium chloride 1gm daily per orally for 12 weeks
Study: NCT00930462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)
Description: Plastic cap fitted on the colonoscope
Study: NCT01848171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-thyroxine
Study: NCT04010279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation with 100% O2, fresh gas flow rate 12 L/minute
Description: volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation with 100% O2, fresh gas flow rate 12 L/minute
Description: volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoxygenation with 100% O2, fresh gas flow rate 12 L/minute
Description: volunteers will be placed in supine position, fresh gas flow rate will be set at 12 L/min and delivered oxygen concentration will be set at 100%.
Study: NCT00897117

Intervention type: GENETIC
Intervention: gene expression analysis
Description: Blood and lung tissue collection

Intervention type: GENETIC
Intervention: microarray analysis
Description: Blood and lung tissue collection

Intervention type: GENETIC
Intervention: protein expression analysis
Description: Blood and lung tissue collection

Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Blood and lung tissue collection

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Blood and lung tissue collection

Intervention type: OTHER
Intervention: matrix-assisted laser desorption/ionization time of flight mass spectrometry
Description: Blood and lung tissue collection
Study: NCT01531400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-selected music
Description: Investigators played self-selected background music in the music group
Study: NCT02338817

Intervention type: DEVICE
Intervention: Diabetes Sentry
Description: The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.

Intervention type: DEVICE
Intervention: Diabetes Sentry
Description: The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
Study: NCT02065180

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: commercially available nutrition supplement
Description: the food supplement contains red rice yeast and olive extract

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02381236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-202
Description: G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
Study: NCT04734054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Hyrax Palatal Expander
Description: The rapid maxillary expansion will be performed. The expansion should be accomplished between 10 to 15 days at most. The screw is going to be turned in a rapid manner.
Study: NCT02072642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active light therapy : Light therapy: DayVia lamp 10000 lux
Description: 4 weeks of active light therapy with DayVia lamp 10000 lux

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo light therapy
Description: 4 weeks with Placebo light therapy
Study: NCT01656044

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: wound care management
Description: Receive SSD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound care management
Description: Receive NPT
Study: NCT01487083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomaglumetad methionil
Description: Administered orally
Study: NCT02115984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panagen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
Study: NCT04390646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH, gonadorelin acetate
Description: Drug administered by a subcutaneous pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl
Description: Drug administered by a subcutaneous pump
Study: NCT02143232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote patient monitoring (Telus RPM)
Description: All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
Study: NCT05415293

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Expecta 200mg DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Promise 275mg DHA
Study: NCT04175171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coprelotamab Injection
Description: The single intravenous infusion of 8mg/kg Coprelotamab shall be administered within 90 minutes through infusion pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Injection
Description: The single intravenous infusion of 8mg/kgTrastuzumab shall be administered within 90 minutes through infusion pump.
Study: NCT02686853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Study: NCT01898403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green solution
Description: Administered peri-tumoral and intradermally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan blue (ISB)
Description: Administered peri-tumoral and intradermally

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)
Study: NCT04182958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (14C)-OPC-61815
Description: On the morning of Day 1, all subjects will receive a single IV infusion of (14C) OPC-61815
Study: NCT02204943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biomarker analysis
Description: Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of radium-223
Description: Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
Study: NCT00634478

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pre-lemniscal Radiation Deep Brain Stimulation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Pre-lemniscal Radiation Deep Brain Stimulation
Study: NCT02389660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended Cognitive Behavioural Therapy (CBT)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Study: NCT03147872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2% Oxygen
Description: 2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
Study: NCT04734054

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Palatal Expander
Description: The slow maxillary expansion will be performed. The expansion will be performed in a slow manner. Patients may need between 6 to 8 months to achieve the required expansion.
Study: NCT00619749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: juice rich in polyphenols
Description: juice during 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: juice poor in polyphenols
Description: juice during 2 weeks
Study: NCT03331913

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin type A (intradermal / submucosal injection at pain area)
Description: Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin type A (intra-masseter injection on the ipsilateral of pain involved)
Description: Comparison of two different treatment methods of Botulinum Toxin type A for the treatment of trigeminal neuralgia
Study: NCT01253018

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot Therapy
Description: Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transition to Task Training
Description: Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
Study: NCT02506049

Intervention type: DEVICE
Group type: OTHER
Intervention: S-LPC:Selective Laser Photocoagulation
Description: Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
Study: NCT01369264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: true left high frequency
Description: 10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Passive sham left high frequency
Description: 10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
Study: NCT02378389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib/Pyrotinib with Docetaxel
Description: Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
Study: NCT01660009

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic clamping
Description: During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic clamping
Description: During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
Study: NCT03815682

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm A: RPTR-147:1
Description: Escalating doses of RPTR-147:1 as a monotherapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm B: RPTR-147:1 and Pembrolizumab
Description: Escalating doses of RPTR-147:1 in combination with Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Arm C: RPTR-147:2
Description: Escalating doses of RPTR-147:2 in patients with HPV positive tumors
Study: NCT02316951

Intervention type: DEVICE
Intervention: single-arm study group
Description: Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
Study: NCT02576587

Intervention type: OTHER
Group type: OTHER
Intervention: Continuous Positive Airway Pressure
Description: For cases, those found to have moderate sleep apnea (AHI \>=15) will be place on CPAP therapy.
Study: NCT01712945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alemtuzumab
Description: Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
Study: NCT02328859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Gait Training
Description: A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill Gait Training
Description: A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
Study: NCT02405143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tACS using DC-Stimulator MC
Description: Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation using DC-Stimulator MC
Description: Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
Study: NCT01204710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: 15 milligrams per kilogram (mg/kg) intravenous (IV) Days 1 and 8
Study: NCT03464760

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3.5g of spirulina per day in 1% silicone
Description: 5 tablets of 700mg per day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 tablets per day of potato-based placebo
Study: NCT01502085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat, Lenalinomide and Dexamethasone
Description: Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21~\* Lenalidomide dose for patients with renal impairment (CrCL\<50ml/min) has be dose adjusted according to package insert~Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above
Study: NCT02390271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotion focused therapy training
Description: The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
Study: NCT01334294

Intervention type: DEVICE
Intervention: ForeseeHome
Description: The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
Study: NCT05596071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil Citrate
Description: Intraoperative loading dose of sufentanil 0.6μg/kg, each additional hour 10μg, within one hour of the end of surgery to stop additional.Postoperative analgesia pump formula: sufentanil 150ug + 0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine 0.75% Injectable Solution
Description: Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% Injectable Solution
Description: Intraoperative epidural analgesia was performed with 0.5% ropivacaine 5-20 ml,Postoperative analgesia pump formula:0.75% ropivacaine 60ml with 0.9% saline diluted to 220ml, 3ml/h, Blos 3ml, locking time 15min, the maximum dose of 36ml in 4 hours Saline is used to dilute other drugs

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Epidural catheter
Description: Intraoperative and postoperative analgesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural catheter
Description: Intraoperative and postoperative analgesia
Study: NCT01088633

Intervention type: OTHER
Group type: OTHER
Intervention: Exhaled particle analysis
Description: At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.~Visit 3:~After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2.
Study: NCT05875688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cementation Technique C
Description: * The utilisation of an appropriate quantity of cement.~* The mitigation of cement waste.~* Prolonged retention of dental crowns.
Study: NCT03309449

Intervention type: DEVICE
Group type: OTHER
Intervention: Syringe and needle
Description: Intramuscular administration of simulated naloxone
Study: NCT01332825

Intervention type: OTHER
Group type: OTHER
Intervention: saline nasal irrigation
Description: subjects irrigate with nasal saline daily for one week
Study: NCT02984982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab SAR236553
Description: Pharmaceutical form: Solution for injection~Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate
Description: Pharmaceutical form: tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT01204710

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 12 milligrams per square meter (mg/m²) IV Day 1~Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤144 mg/m²)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg orally (PO) twice daily (BID) on each day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg orally (PO) twice daily (BID) on each day